ReViral Appoints Alex C. Sapir as CEO
"Today, ReViral has a rich pipeline of wholly-owned RSV antiviral product candidates and strong research," said Dr. Kenneth Powell, Chairman of the Board. "Alex's proven leadership skills combined with his deep experience building biotech businesses make him ideally suited to take ReViral to the next level. On behalf of the Board of Directors, I’d also like to thank Eddy for his successful time at ReViral as CEO, where we now see the Company’s lead product, sisunatovir (RV521), poised to enter international, pediatric Phase II clinical trials this year. His leadership has been instrumental to ReViral’s evolution, and we look forward to benefiting from his continued input and guidance as COO.”
Mr. Sapir brings to ReViral many years of combined strategic and commercial experience in the biotechnology industry. From 2016 through 2018, Alex was the President and CEO at Dova Pharmaceuticals (NASDAQ: DOVA). During Alex’s tenure, the company raised $160M through a successful Initial Public Offering (IPO) and subsequent follow-on offering. With those proceeds Dova Pharmaceuticals grew from a small, private, pre-commercial company to a 150-person, fully-integrated, publicly-traded biotech company with an approved and marketed product and a rich pipeline of ongoing clinical programs.